Forma Therapeutics Holdings LLC is going to put its unusual corporate structure to a new test. The firm announced on Tuesday, July 9 a collaboration with Cancer Research Technology Ltd., the for-profit arm of Cancer Research UK, to discover drugs that target a large protein family with implications in the broad and emerging field of protein homeostasis.
As Forma and CRT advance compounds that target deubiquitinating enzymes, they will create separate corporate entities to house the drug...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?